Seroprevalence of IgA anti Epstein-Barr virus is high among family members of nasopharyngeal cancer patients and individuals presenting with chronic complaints in head and neck area

Susanna Hilda Hutajulu1*, Jajah Fachiroh2*, Gabriella Argy3, Sagung Rai Indrasari4, Luh Putu Lusy Indrawati4, Dewi Kartikawati Paramita2, Theodola Baning Rahayu Jati5, Jaap M. Middeldorp6

1 Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Universitas Gadjah Mada/Dr. Sardjito Hospital, Yogyakarta, Indonesia, 2 Department of Histology and Cell Biology, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia, 3 Study Program of Medicine, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia, 4 Department of Otorhinolaryngology Head and Neck Surgery, Faculty of Medicine, Universitas Gadjah Mada/Dr. Sardjito Hospital, Yogyakarta, Indonesia, 5 Field Epidemiology Training Program, Department of Public Health, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia, 6 Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands

These authors contributed equally to this work.
*jajahfachiroh@ugm.ac.id

Abstract

Epstein-Barr (EBV) infection and presence of a nasopharyngeal cancer (NPC) case in the family increases the risk of developing NPC. Aberrant anti-EBV immunoglobulin A (IgA) antibodies (EBV-IgA) may be present in the sera of non-cancer individuals and predict NPC. Limited studies report the presence of EBV-IgA antibodies within non-cancer individuals in Indonesia where the disease is prevalent. This study aimed at exploring whether EBV-IgA was found more frequently among first degree relatives of NPC patients and individuals presenting with chronic symptoms in the head and neck region compared to healthy controls. A total of 967 non-cancer subjects were recruited, including 509 family members of NPC cases, 196 individuals having chronic complaints in the head and neck region, and 262 healthy donors of the local blood bank. Sera were analyzed using a standardized peptide-based EBV-IgA ELISA. Overall, 61.6% of all individuals had anti-EBV IgA reactivity equal to or below cut off value (CoV). Seroreactivity above CoV was significantly higher in females (38.7%) compared to males (28.7%) (p = 0.001). Older individuals had more seroreactivity above CoV (42.5%) than the younger ones (26.4%) (p < 0.001). Seroprevalence was significantly higher in family members of NPC patients (41.7%), compared to 32.7% of individuals with chronic head and neck problems (p = 0.028) and 16.4% healthy blood donors (p < 0.001). As conclusion, this study showed a significant higher seroprevalence in healthy family members of NPC cases and subjects presenting with chronic symptoms in the head and neck area compared to healthy individuals from the general community. This
finding indicates that both groups have elevated risk of developing NPC and may serve as targets for a regional NPC screening program.

**Introduction**

Nasopharyngeal carcinoma (NPC), a relatively rare cancer in many regions of the world, has a high incidence and mortality in Southeast Asia including Indonesia. Based on local data, its incidence in the country is 6.2 cases per 100,000 population annually, representing the fourth most prevalent cancer in men [1], with most cases being histologically undifferentiated carcinoma [2]. Considering the size of the Indonesian population, about 13,000 new cases of NPC may occur per year, making it a significant national health burden.

The evolution of NPC results from an interaction of genetic factors and environmental influences, including Epstein-Barr virus (EBV) infection. EBV infection has a strong, consistent implication in the pathogenesis of NPC especially the undifferentiated disease [3–5]. The close relationship between EBV and NPC is underscored by the existence of viral DNA, RNA, and protein in all tumor cells, viral reactivation and particular antibodies against EBV antigens in the sera of patients [6,7]. Deviant antibodies against EBV antigens such as viral capsid antigen (VCA), DNase, early antigen (EA), and EBV nuclear antigen 1 (EBNA1) have been proposed for clinical diagnosis [8–11]. We have developed an IgA-EBV diagnostic tool, based on reactivity against EBNA1 and VCA-p18 in one reaction. EBNA-1 is a latent protein expressed in all EBV infected (tumor) cells and responsible for maintenance of the latent EBV episome [12]. VCA-p18 protein is part of the viral capsid, released from virus producing cells [13]. The EBV-IgA ELISA method has been used to select high risk individuals in healthy populations [14] and predicting disease relapse [15]. Multiple studies demonstrated that markedly high EBV-IgA reactivity is detectable in NPC cases preceding clinical symptoms supporting the use of EBV-IgA serology for NPC screening in endemic regions [16–20].

Many reports showed that first-degree relatives of NPC cases are at a higher risk of developing the malignancy when compared to non-family individuals [21–25]. Moreover, family members are considered primary targets for a NPC screening [26–28]. Besides this population, individuals with a history of unexplained chronic nasal, neurological and otological problems have been observed to have risk for NPC development [29–31]. Indeed, patients with NPC frequently present with non-specific symptoms associated with NPC development, such as epistaxis, nasal blockage and discharge, tinnitus and deafness, headaches, diplopia, facial pain and numbness, and swollen lymph nodes in the neck [32].

Frequency of EBV-IgA seroreactivity among healthy individuals has not been extensively analyzed in Indonesia. Our previous work has demonstrated that close family members of NPC cases in the Yogyakarta region had a higher frequency of elevated IgA seroreactivity against EBV-EBNA-1 and -VCA/p18, compared to community controls of NPC cases [14]. Considering that people with chronic problems in the head and neck area may be at risk of developing NPC and may have similar features of immune response against EBV, this study aimed to compare antibody reactivity in the sera of family members of NPC cases with individuals who presented with such complaints. Furthermore, we compare immune response against EBV in both groups versus regional healthy subjects recruited from the local blood bank. Importantly, this approach will determine whether any serological marker differences can be used to identify NPC cases among the family and clinical groups compared to healthy
controls. This analysis will provide evidence for utility of IgA serology for NPC screening in the general population in Indonesia.

**Methods**

**Study population**

Data from three studies performed in the Yogyakarta region and coordinated from the Dr. Sardjito Hospital were analyzed for comparison of anti-EBV antibody titers across first-degree relatives of NPC patients, individuals with chronic symptoms in the head and neck areas, and healthy individuals from the local blood bank. The Human Subjects review committee in Yogyakarta approved these projects and informed consent was obtained from all subjects. The family study and the study on patients with chronic head and neck problems were conducted in about the same time period and used similar data collection instruments and same laboratory tests [10,14]. Enrollment of healthy participants from the blood bank was done three years after the two studies finished.

In the family study, 509 first-degree relatives were enrolled and home-visited. Family relatives were defined as fathers, mothers, siblings and off-springs living in the same residence or neighborhood of particular NPC cases. This study was done between year 2008 and 2010. One-hundred and ninety-six subjects with chronic problems in the head and neck area were recruited at the Department of Otorhinolaryngology Head and Neck Surgery, Dr. Sardjito Hospital from July 2006 to December 2010. Recruited subjects came to the department with chronic complaints that lasted for at least 3 months which were not responsive to standard treatment (such as antibiotics, or anti-allergics) for more than 3 times. The clinical symptoms included rhinitis, nasal obstruction, epistaxis, tinnitus, hearing impairment, ear discomfort (sensation of fullness or pain), headache, facial pain, dizziness and dysphagia. These patients were selected for having symptoms in the spectrum characteristics of NPC in early disease [2]. Two-hundred and sixty-two healthy individuals were enrolled from the blood banks of City of Yogyakarta and Sleman District, Yogyakarta, in 2013. These healthy subjects had resided in the province at least for five years and had no recorded symptoms of any malignancy nor chronic disease in the head and neck region and had no family history of NPC. Demography data including age and sex were also included.

**Ethics approval and consent to participate**

The Human Subjects review committee in Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia (committee’s reference numbers: KE/FK/58/EC and KE/FK/336/EC) approved these projects and informed consent was obtained from all subjects prior to any data acquisition, sample collection, or data analysis.

**Blood sample and EBV serology**

Blood sampling was done from the arm vein in all subjects. For individuals who rejected having venous blood drawn, blood was taken using a finger prick method as described previously [33]. Serology analysis was performed by ELISA using a combination of two EBV antigens, i.e. EBNA1 as viral latent antigen and VCA-p18 as lytic antigen. Immunoglobulin A (IgA) reactivity against EBNA1 plus VCA-p18 was analyzed in ELISA using a peptide-based antigen combination. [10] A positive result was defined as optical density (OD)_{450} > 0.354, as defined before and all procedures and definition of CoV were characterized elsewhere [10]. This assay showed a good sensitivity (90.1%) and specificity (85.4%) in discriminating NPC cases from non-cancer controls. Further the assay is referred as EBV-IgA ELISA.
Statistical analysis

The difference of distribution of EBV antibody status among three different studies was analyzed using the Pearson’s $\chi^2$ test. To evaluate possible demographic determinants of EBV-IgA seroreactivity, factors including age and gender were also compared using the Pearson’s $\chi^2$ test. Continuous variables were tested using the Mann-Whitney U-test. All tests were obtained using SPSS 24. All p-values presented were two-sided with $p \leq 0.05$ defined as statistically significant.

Results

A total of 967 non-cancer subjects were recruited. The ages of all participants ranged from 18–80 years. The characteristics of subjects among different populations are shown in Table 1. The family study group and patients with chronic head and neck complaints were dominated by females (51.7% and 60.7%, respectively), while the group of healthy participants from the blood bank was dominated by males (87.0%) ($p < 0.001$). Older individuals aged >40 years were prominent in the family study group (52.3%), while younger participants dominated the other two groups (60.2% and 80.5%, respectively) ($p < 0.001$). Overall, OD$_{450}$ values of anti-EBV IgA (seroreactivity) of all subjects ranged from zero to 3.408. There were 648 out of 967 (61.7%) individuals having anti-EBV IgA antibody titer equal or below CoV and 319 (30.4%) individuals showing reactivity above CoV. Frequency of seroreactivity above CoV (seroprevalence) was significantly higher in females (161/416; 38.7%) compared to males (158/551; 28.7%) ($p = 0.001$), with mean $\pm$ standard of deviation (SD) of 0.407$\pm$0.592 and 0.521$\pm$0.683, respectively. When discriminated by age using 40 years as a CoV [2,34], the older group showed significantly higher seroprevalence (168/395; 42.5%) than the younger group (151/572; 26.4%) ($p < 0.001$), with mean $\pm$ SD of 0.591$\pm$0.773 and 0.363$\pm$0.499, respectively.

The median values of seroreactivity against EBV in the sera of the three populations were 0.289, 0.232, and 0.152, respectively. There were few differences between median values of seroreactivity in the NPC family member group and in subjects with chronic head and neck

|                  | First-degree relatives of NPC cases (n = 509) | Subjects with chronic problems in head and neck (n = 196) | Subjects from the local blood bank (n = 262) | P value |
|------------------|-----------------------------------------------|----------------------------------------------------------|---------------------------------------------|---------|
| **Sex**          |                                               |                                                          |                                             |         |
| Males            | 246 (48.3)                                    | 77 (39.3)                                                | 228 (87.0)                                  | <0.001  |
| Females          | 263 (51.7)                                    | 119 (60.7)                                               | 34 (13.0)                                   |         |
| **Age**          |                                               |                                                          |                                             |         |
| ≤40 years        | 243 (47.7)                                    | 118 (60.2)                                               | 211 (80.5)                                  | <0.001  |
| >40 years        | 266 (52.3)                                    | 78 (39.8)                                                | 51 (19.5)                                   |         |
| **EBV-IgA values**|                                               |                                                          |                                             |         |
| Mean level ± SD  | 0.550$\pm$0.722                               | 0.440$\pm$0.616                                          | 0.284$\pm$0.383                             |         |
| Median value     | 0.289                                         | 0.232                                                    | 0.152                                       |         |
| Range of value   | 0.001–3.408                                   | 0.000–3.380                                              | 0.001–0.249                                 |         |
| **EBV-IgA**      |                                               |                                                          |                                             |         |
| ≤CoV (seronegative) | 297 (58.3)                                      | 132 (67.3)                                               | 219 (83.6)                                  | <0.001  |
| >CoV (seropositive) | 212 (41.7)                                      | 64 (32.7)                                                | 43 (16.4)                                   |         |

*Normalized values

https://doi.org/10.1371/journal.pone.0180683.t001
complaints (p = 0.062). Significant differences were observed when comparing median values of seroreactivity in the groups of NPC family members and patients with chronic disease with blood bank donors (p values for both comparisons <0.001) (Table 1). Fig 1 demonstrates a boxplot of normalised EBV-IgA ELISA seroreactivity in the three groups.

EBV-IgA seropositivity was shown by 212 family members of NPC patients (41.7%), compared to 64 individuals with chronic head and neck problems (32.7%) and 43 healthy individuals (16.4%) recruited from the blood bank (p<0.001). A significant difference in seroprevalence was also found between NPC relatives and patients with chronic head and neck problems (p = 0.028).

Table 2 shows the distribution of EBV-IgA seroreactivity by sex and age in each group. In all groups seroprevalence was higher in females and older subjects than their counterparts. The difference in seroprevalence between genders in the three groups was small. For age classification, significant differences were observed in subjects presenting with chronic complaints (p = 0.008) and community healthy subjects (p = 0.005).

To analyze the elevated antibody levels observed among these non-cancer populations, the distribution of seropositivity by gender and age across the three populations was further evaluated (Table 3). Data showed that for both sexes and age classifications, seroprevalence was
higher in the group of family members of NPC cases and subjects who presented with chronic head and neck symptoms compared to healthy participants in general community. Significant differences were shown for all determinants except older age.

**Discussion**

Nasopharyngeal carcinoma (NPC) is characterized by a late clinical presentation due to the hidden site of primary tumor formation and non-specific symptoms at an early stage. Disease diagnosis at the preclinical stage is of crucial importance to improve treatment efficacy and patient survival. The consistent presence of EBV components especially among NPC in endemic populations has pushed for the development of EBV-based diagnostic methods. Regardless of the development of technology in detecting EBV DNA from tissue or peripheral blood of NPC patients, the use of non-invasive serology is more suitable for screening purpose.

| Table 2. Distribution of seroprevalence by sex and age in the three groups. |
|----------------|----------------|----------------|----------------|
|                | Number | Number (%) positive | P value |
| **First-degree relatives of NPC cases** | 509 | | |
| Sex | | | |
| Males | 246 | 101 (41.9) | 0.793 |
| Females | 263 | 111 (42.2) | |
| Age | | | |
| ≤40 years | 243 | 93 (38.3) | 0.139 |
| >40 years | 266 | 119 (44.7) | |
| **Subjects with chronic problems in head and neck area** | 196 | | |
| Sex | | | |
| Males | 77 | 21 (27.3) | 0.196 |
| Females | 119 | 43 (36.1) | |
| Age | | | |
| ≤40 years | 118 | 30 (25.4) | 0.008 |
| >40 years | 78 | 34 (43.6) | |
| **Subjects from the local blood bank** | 262 | | |
| Sex | | | |
| Males | 228 | 36 (15.8) | 0.481 |
| Females | 34 | 7 (20.6) | |
| Age | | | |
| ≤40 years | 211 | 28 (13.3) | 0.005 |
| >40 years | 51 | 15 (29.4) | |

https://doi.org/10.1371/journal.pone.0180683.t002

| Table 3. Distribution of seroprevalence by sex and age across three groups. |
|----------------|----------------|----------------|----------------|
|                | First-degree relatives of NPC cases (n = 509) n (%) | Subjects with chronic problems in head and neck area (n = 196) n (%) | Subjects from the local blood bank (n = 262) n (%) | P value |
| Male sex | 101/246 (41.1) | 21/77 (27.3) | 36/228 (15.8) | < 0.001 |
| Female sex | 111/263 (42.2) | 43/119 (36.1) | 7/34 (20.6) | 0.041 |
| Age of ≤40 years | 93/243 (38.3) | 30/118 (25.4) | 28/211 (13.3) | < 0.001 |
| Age of >40 years | 119/266 (44.7) | 34/78 (43.6) | 15/51 (29.4) | 0.125 |

https://doi.org/10.1371/journal.pone.0180683.t003
due to its high predictive value and its cost efficiency [35,36]. Regular serological follow-up to observe dynamic fluctuations of anti EBV-IgA in time is recommended for a NPC secondary prevention program [19,37,38]. The current study provides the first data on IgA seroreactivity against EBV antigens in non-cancer subjects from Indonesia, where NPC is a prevalent malignancy [2]. However, the multiple ethnicities in Indonesia may interfere with a homogenicity pattern of seropositivity. Results from this study provide a first basis for NPC screening in Indonesia.

Zou et al. reported that an individual with family history of NPC had 14.2 times higher risk of NPC development compared to individuals without a family history of NPC [30]. Pickard et al. employed IgA-VCA, DNase neutralizing activity, and IgA-EBNA1, and showed that seroprevalence in unaffected family members of NPC cases was 5–6 times significantly higher than in members of the community. The report showed that IgA-VCA, DNase neutralizing antibody, and IgA-EBNA-1 among unaffected family members of NPC were 28.4%, 11.8% and 20.1%, respectively [39]. However, for positivity to any of these three markers, the seroprevalence increased to 47.9%. This proportion was similar to our previous finding (41.7%) in local populations using combined VCA-p18/EBNA-1 IgA-detection in one ELISA test [14]. This result further confirms that the use of multiple antigens of EBV provided better detection [10,40].

In this current study we observed that EBV-IgA seroprevalence in family members of NPC was significantly higher than that of normal healthy subjects without a family link to NPC (41.7% versus 16.4%, p<0.001). This finding deviates from our previous results showing similar frequency of seroreactivity between first degree relatives of NPC cases and healthy matched controls living in the neighborhood (41.2 versus 39.2%, p = 0.770) [14]. More healthy participants (n = 967) recruited in the present study compared to our previous study (n = 86) may affect this difference. Healthy population-based controls living in the same area with NPC cases [14] might share environmental exposures with the NPC cases, leading to rather high seroreactivity in the population previously reported. Moreover, different recruitment protocol in the present study might contribute to this discordance since all healthy subjects enrolled were more strictly selected by infection screening and clinical eligibility.

Late clinical presentation of NPC is influenced by unspecific disease symptoms. Multiple head and neck complaints are observed in the early clinical stages of NPC [32]. Ekburanawat et al. (2010) and Zhou et al. (2000) showed that past history of chronic nasal and/or otological disease were related to NPC risk by showing an odds ratio (OR) of 2.71 (95% confidence interval/CI = 1.45–5.06) and 3.6 (95% CI = 1.3–10.1), respectively [29,30]. These studies additionally demonstrated that the symptoms might be simultaneously observed with elevated titer to anti-EBV IgA [19]. The inflammatory and other particular benign conditions in such areas can further predispose the nasopharyngeal mucosa to transformation on exposure to carcinogenic substances in the environment [29]. Our findings showed that seroprevalence in subjects with chronic complaints in head and neck area was significantly higher than that of healthy subjects, indicating that these individuals are also suitable targets for early detection program in our region. Moreover, seroprevalence in this group was significantly lower than that of first degree relatives of NPC patients. This result can be affected by close genetic association and similar environmental exposure among family members.

In a NPC endemic region, most healthy populations are considered to have a latent state of EBV infection, marked by low or absent anti-EBV IgG or IgA titer, respectively. Upon exposure to EBV-lytic activation substances (nitrosamine, UV, butyrates, phorbol esters), local immune suppression, or glucocorticoid-inducing stress, EBV might be driven to enter the lytic state [41–45]. This process might be reflected by elevated IgG or IgA anti EBV titers [19].
Within the total of our study populations, we observed that seroprevalence was higher among females and those of older age, which is in agreement with Du et al. (2016) [38]. It is assumed that older subjects had more exposure to EBV triggers along with weakening of immune response which may facilitate EBV reactivation, leading to elevated IgA anti EBV. Some reports demonstrated that seroreactivity against EBV in females was stronger than in males, possibly due to hormonal effects on immunologic responses [46,47].

Cohort studies for early detection of NPC have been reported recently involving populations in Southern China and Taiwan [19,35,37,48]. In Indonesia issues are still being raised regarding populations to target and suitable screening methods. This study confirms that in Yogyakarta region seroprevalence of IgA anti EBV is higher among NPC relatives and individuals presenting with chronic symptoms in the head and neck area compared to regional healthy individuals. It is also proposed that the combined analysis of IgA to [VCA-p18+EBNA-1] in one assay may be suitable for NPC screening in Indonesia.

Conclusion
This study demonstrated a significant higher seroprevalence in healthy family members of NPC cases and subjects presenting with chronic complaints in the head and neck area compared to healthy subjects. Defined as high responders, these groups of individuals are considered as candidates for an NPC screening program.

Acknowledgments
We thank Bambang Hariwiyanto, MD, PhD and Camelia Herdini, MD and staffs at Department of Otorhinolaryngology Head and Neck Surgery, Dr Sardjito Hospital for clinical support; Indonesia Red-Cross (blood bank) City of Yogyakarta and Sleman District for the collaboration in normal blood sample collection. We also thank Rosidah and Fransiska Erna Damayanti for epidemiological assistance, and Sumartiningsih, Yuli Kristianto, Arina Prihestri Nugraheni, Christine Fatmawati, Rahma Yuantari, Sri Fatimawati and Dewi Sulistyawati for technical assistance. We gratefully acknowledge Nuffic/Netherland Fellowship Program (NFP-PhD 08–36), Dutch Cancer Society (KWF IN-2004-17) and Grants of Public Fund (Hibah Dana Masyarakat) 2013, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia for grant fundings. Finally, we thank Adrian Coen and staff of Klinik Bahasa, Office for Research and Publication, Faculty of Medicine, Universitas Gadjah Mada for proofreading the text.

Author Contributions

Conceptualization: Susanna Hilda Hutajulu, Jajah Fachiroh, Dewi Kartikawati Paramita, Jaap M. Middeldorp.

Data curation: Susanna Hilda Hutajulu, Jajah Fachiroh, Gabriella Argy, Luh Putu Lusy Indrawati, Theodola Baning Rahayu Jati.

Formal analysis: Susanna Hilda Hutajulu, Jajah Fachiroh, Gabriella Argy.

Funding acquisition: Susanna Hilda Hutajulu, Jajah Fachiroh, Dewi Kartikawati Paramita, Jaap M. Middeldorp.

Investigation: Susanna Hilda Hutajulu, Jajah Fachiroh, Gabriella Argy, Sagung Rai Indrasari, Luh Putu Lusy Indrawati, Dewi Kartikawati Paramita, Theodola Baning Rahayu Jati.
Methodology: Susanna Hilda Hutajulu, Jajah Fachiroh, Gabriella Argy, Sagung Rai Indrasari, Luh Putu Lusy Indrawati, Dewi Kartikawati Paramita, Theodola Baning Rahayu Jati, Jaap M. Middeldorp.

Project administration: Susanna Hilda Hutajulu, Jajah Fachiroh, Dewi Kartikawati Paramita, Jaap M. Middeldorp.

Resources: Susanna Hilda Hutajulu, Jajah Fachiroh, Gabriella Argy, Sagung Rai Indrasari, Luh Putu Lusy Indrawati, Dewi Kartikawati Paramita, Theodola Baning Rahayu Jati, Jaap M. Middeldorp.

Software: Susanna Hilda Hutajulu, Jajah Fachiroh, Theodola Baning Rahayu Jati.

Supervision: Susanna Hilda Hutajulu, Jajah Fachiroh, Sagung Rai Indrasari, Luh Putu Lusy Indrawati, Theodola Baning Rahayu Jati.

Validation: Susanna Hilda Hutajulu, Jajah Fachiroh, Gabriella Argy, Theodola Baning Rahayu Jati.

Visualization: Susanna Hilda Hutajulu, Jajah Fachiroh.

Writing – original draft: Susanna Hilda Hutajulu, Jajah Fachiroh.

Writing – review & editing: Susanna Hilda Hutajulu, Jajah Fachiroh, Jaap M. Middeldorp.

References

1. Soeripto. Epidemiology of nasopharyngeal carcinoma. Berita Kedokteran Masyarakat (Ina). 1998; 13:207–211.

2. Adham M, Kurniawan AN, Muhtadi AI, Roezin A, Hermani B, Gondhowiardjo S, et al. Nasopharyngeal carcinoma in Indonesia: epidemiology, incidence, signs, and symptoms at presentation. Chin J Cancer. 2012; 31(4):185–196. https://doi.org/10.5732/cjc.011.10328 PMID: 22313595

3. zur Hausen H, Schulte-Holthausen H, Klein G, Henle W, Henle G, Clifford P, et al. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature. 1970; 228(5276):1056–1058. PMID: 4320657

4. Raab-Traub N. Epstein-Barr virus infection in nasopharyngeal carcinoma. Infect Agents Dis. 1992; 1(4):173–184. PMID: 1365543

5. Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2006; 15(10):1765–1777. https://doi.org/10.1158/1055-9966.EPI-06-0353 PMID: 17035381

6. Hildesheim A, Levine PH. Etiology of nasopharyngeal carcinoma: a review. Epidemiol Rev. 1993; 15(2):466–485. PMID: 8174667

7. Middeldorp JM, Brink AA, van den Brule AJ, Meijer CJ. Pathogenic roles for Epstein-Barr virus (EBV) gene products in EBV-associated proliferative disorders. Crit Rev Oncol Hematol. 2003; 45(1):1–36. PMID: 12482570

8. Henle G, Henle W. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer. 1976; 17(1):1–7. PMID: 175020

9. Chen JY, Liu MY, Chen CJ, Hsu MM, Tu SM, Lee HH, et al. Antibody to Epstein-Barr virus-specific DNase as a marker for the early detection of nasopharyngeal carcinoma. J Med Virol. 1985; 17(1):47–49. PMID: 2995572

10. Fachiroh J, Paramita DK, Hariwijayanto B, Harijadi A, Dahlia HL, Indrasari SR, et al. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening. J Clin Microbiol. 2006; 44(4):1459–1467. https://doi.org/10.1128/JCM.44.4.1459-1467.2006 PMID: 16597877

11. Paramita DK, Fachiroh J, Haryana SM, Middeldorp JM. Two-step Epstein-Barr virus immunoglobulin A enzyme-linked immunosorbent assay system for serological screening and confirmation of nasopharyngeal carcinoma. Clin Vaccine Immunol. 2009; 16(5):706–711. https://doi.org/10.1128/CVI.00425-08 PMID: 19321695
12. Yates JL, Warren N, Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature. 1985; 313(6005):812–815.

13. Mettenleiter TC: Herpesvirus assembly and egress. J Virol. 2002; 76(4):1537–1547. https://doi.org/10.1128/JVI.76.4.1537-1547.2002 PMID: 11799148

14. Hutajulu SH, Ng N, Jati BR, Fachiroh J, Herdini C, Hariyanto B, et al. Seroreactivity against Epstein-Barr virus (EBV) among first-degree relatives of sporadic EBV-associated nasopharyngeal carcinoma in Indonesia. J Med Virol. 2012; 84(5):768–776. https://doi.org/10.1002/jmv.23263 PMID: 22431025

15. Wildeman MA, Fles R, Herdini C, Indrasari RS, Vincent AD, Tjokronagoro M, et al. Primary treatment results of Nasopharyngeal Carcinoma (NPC) in Yogyakarta, Indonesia. PLoS One. 2013; 8(5):e63706. https://doi.org/10.1371/journal.pone.0063706 PMID: 23675501

16. Zeng J, Gong CH, Jan MG, Fun Z, Zhang LG, Li HY. Detection of Epstein-Barr virus IgA/EA antibody for diagnosis of nasopharyngeal carcinoma by immunoautoradiography. Int J Cancer. 1983; 31(5):599–601. PMID: 6309967

17. Chen JY, Chen CJ, Liu MY, Cho SM, Hsu MM, Lynn TC, et al. Antibody to Epstein-Barr virus-specific DNase as a marker for field survey of patients with nasopharyngeal carcinoma in Taiwan. J Med Virol. 1989; 27(4):269–273. PMID: 2542436

18. Chien YC, Chen JY, Liu MY, Yang HI, Hsu MM, Chen CJ, et al. Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med. 2001; 345(26):1877–1882. https://doi.org/10.1056/NEJMoa011610 PMID: 11756578

19. Ji MF, Wang DK, Yu YL, Guo YQ, Li Q, Cheng WM, et al. Sustained elevation of Epstein-Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma. Br J Cancer. 2007; 96(4):623–630. https://doi.org/10.1038/sj.bjc.6603609 PMID: 17285127

20. Li S, Deng Y, Li X, Chen QP, Liao XC, Qin X. Diagnostic value of Epstein-Barr virus capsid antigen-IgA in nasopharyngeal carcinoma: a meta-analysis. Chin Med J (Engl). 2010; 123(9):1201–1205.

21. Ireland B, Lanier AP, Knutson L, Clift SE, Harpster A. Increased risk of cancer in siblings of Alaskan native patients with nasopharyngeal carcinoma. Int J Epidemiol. 1988; 17(3):509–511. PMID: 3209327

22. Loh KS, Goh BC, Lu J, Hsieh WS, Tan L. Familial nasopharyngeal carcinoma in a cohort of 200 patients. Arch Otolaryngol Head Neck Surg. 2006; 132(1):82–85. https://doi.org/10.1001/archotol.132.1.82 PMID: 16415435

23. Friberg J, Wohlfahrt J, Koch A, Storm H, Olsen OR, Melbye M. Cancer susceptibility in nasopharyngeal carcinoma families—a population-based cohort study. Cancer Res. 2005; 65(18):8567–8572. https://doi.org/10.1158/0008-5472.CAN-04-4208 PMID: 16166338

24. Ji X, Zhang W, Xie C, Wang B, Zhang G, Zhou F. Nasopharyngeal carcinoma risk by histologic type in central China: impact of smoking, alcohol and family history. Int J Cancer. 2011; 129(3):724–732. https://doi.org/10.1002/ijc.20596 PMID: 20878958

25. Qin HD, Jia WH, Zhang LL, Liu N, Zhou XX, Wang MH, et al. Elevated Epstein-Barr virus seroreactivity among unaffected members of families with nasopharyngeal carcinoma. J Med Virol. 2011; 83(10):1792–1796. https://doi.org/10.1002/jmv.22121 PMID: 21837797

26. Ng WT, Yau TK, Yung RW, Sze WM, Tsang AH, Law AL, et al. Screening for family members of patients with nasopharyngeal carcinoma. Int J Cancer. 2005; 113(6):998–1001. https://doi.org/10.1002/ijc.20672 PMID: 15515016

27. Ng WT, Choi CW, Lee MC, Law LY, Yau TK, Lee AW. Outcomes of nasopharyngeal carcinoma screening for high risk family members in Hong Kong. Fam Cancer. 2010; 9(2):221–228. https://doi.org/10.1007/s10689-009-9296-y PMID: 19779847

28. Xu BQ, Tu ZW, Tao YL, Liu ZG, Li XH, Yi W, et al. Forty-six cases of nasopharyngeal carcinoma treated with 50 Gy radiotherapy plus hematoporphyrin derivative: 20 years of follow-up and outcomes from the Sun Yat-sen University Cancer Center. Chin J Cancer. 2016; 35:37. https://doi.org/10.1186/s40880-016-0098-y PMID: 27056488

29. Ekburnawat W, Ekpanyasuk C, Brennan P, Kanka C, Tepsuwan K, Temiyasth S, et al. Evaluation of non-viral risk factors for nasopharyngeal carcinoma in Thailand: results from a case-control study. Asian Pac J Cancer Prev. 2010; 11(4):929–932. PMID: 21136003

30. Zou J, Sun Q, Akiba S, Yuan Y, Zha Y, Tao Z, et al. A case-control study of nasopharyngeal carcinoma in the high background radiation areas of Yangjiang, China. J Radiat Res. 2000; 41 Suppl:53–62.

31. Yuan JM, Wang XL, Xiang YB, Gao YT, Ross RK, Yu MC. Non-dietary risk factors for nasopharyngeal carcinoma in Shanghai, China. Int J Cancer. 2000; 85(3):364–369. PMID: 10652428

32. Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet. 2005; 365(9476):2041–2054.

33. Fachiroh J, Prasetyanti PR, Paramita DK, Prasetyawati AT, Anggrahini DW, Haryana SM, et al. Dried-blood sampling for epstein-barr virus immunoglobulin G (IgG) and IgA serology in nasopharyngeal
carcinoma screening. J Clin Microbiol. 2008; 46(4):1374–1380. https://doi.org/10.1128/JCM.01368-07 PMID: 18256216

34. Han-Shiang C. Curative resection of colorectal adenocarcinoma: multivariate analysis of 5-year follow-up. World J Surg. 1999; 23(12):1301–1306. PMID: 10552125

35. Ji MF, Huang QH, Yu X, Liu Z, Li X, Zhang LF, et al. Evaluation of plasma Epstein-Barr virus DNA load to distinguish nasopharyngeal carcinoma patients from healthy high-risk populations in Southern China. Cancer. 2014; 120(9):1353–1360. https://doi.org/10.1002/cncr.28564 PMID: 24477877

36. Coghill AE, Hsu WL, Pfeiffer RM, Juwana H, Yu KJ, Lou PJ, et al. Epstein-Barr virus serology as a potential screening marker for nasopharyngeal carcinoma among high-risk individuals from multiplex families in Taiwan. Cancer Epidemiol Biomarkers Prev. 2014; 23(7):1213–1219. https://doi.org/10.1158/1055-9965.EPI-13-1262 PMID: 24769890

37. Coghill AE, Bu W, Nguyen H, Hsu WL, Yu KJ, Lou PJ, et al. High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma. Clin Cancer Res. 2016; 22(14):3451–3457. https://doi.org/10.1158/1078-0432.CCR-15-2299 PMID: 26920891

38. Du JL, Chen SH, Huang QH, Xie SH, Ye YF, Gao R, et al. Subtype distribution and long-term titer fluctuation patterns of serum anti-Epstein-Barr virus antibodies in a non-nasopharyngeal carcinoma population from an endemic area in South China: a cohort study. Chin J Cancer. 2016; 35(1):78. https://doi.org/10.1186/s40880-016-0130-2 PMID: 27527073

39. Pickard A, Chen CJ, Diehl SR, Liu MY, Cheng YJ, Hsu WL, et al. Epstein-Barr virus seroreactivity among unaffected individuals within high-risk nasopharyngeal carcinoma families in Taiwan. Int J Cancer. 2004; 111(1):117–123. https://doi.org/10.1002/ijc.20222 PMID: 15185352

40. Fachiroh J, Schouten T, Hariwyantoro B, Paramita DK, Harjadi A, Haryana SM, et al. Molecular diversity of Epstein-Barr virus IgG and IgA antibody responses in nasopharyngeal carcinoma: a comparison of Indonesian, Chinese, and European subjects. J Infect Dis. 2004; 190(1):53–62. https://doi.org/10.1086/421245 PMID: 15195243

41. Yu MC, Garabrant DH, Huang TB, Henderson BE. Occupational and other non-dietary risk factors for nasopharyngeal carcinoma in Guangzhou, China. Int J Cancer. 1990; 45(6):1033–1039. PMID: 2351484

42. Ward MH, Pan WH, Cheng YJ, Li FH, Brinton LA, Chen CJ, et al. Dietary exposure to nitrite and nitrosamines and risk of nasopharyngeal carcinoma in Taiwan. Int J Cancer. 2000; 86(5):603–609. PMID: 10797279

43. Lee CH, Fang CY, Sheu JJ, Chang Y, Takada K, Chen JY. Amplicons on chromosome 3 contain oncosenes induced by recurrent exposure to 12-O-tetradecanoylphorbol-13-acetate and sodium n-butyrate and Epstein-Barr virus reactivation in a nasopharyngeal carcinoma cell line. Cancer Genet Cytogenet. 2008; 185(1):1–10. https://doi.org/10.1016/j.cancergenetcyt.2008.03.014 PMID: 18655687

44. Yu MC, Nichols PW, Zou XN, Estes J, Henderson BE. Induction of malignant nasal cavity tumours in Wistar rats fed Chinese salted fish. Br J Cancer. 1989; 60(2):198–201. PMID: 2765365

45. Yang EV, Webster Marketon JL, Chen M, Lo KW, Kim SJ, Glaser R. Glucocorticoids activate Epstein Barr virus lytic replication through the upregulation of immediate early BZLF1 gene expression. Brain Behav Immun. 2010; 24(7):1089–1096. https://doi.org/10.1016/j.bbi.2010.04.013 PMID: 20466055

46. Schuurs AH, Verheul HA. Effects of gender and sex steroids on the immune response. J Steroid Biochem. 1990; 35(2):157–172. PMID: 2407902

47. Wagner HJ, Hornel M, Teichert HM, Kirchner H. Sex difference in the serostatus of adults to the Epstein-Barr virus. Immunobiology. 1994; 190(4-5):424–429. https://doi.org/10.1016/S0171-2985(11)80613-3 PMID: 7982725

48. Lin JH, Jiang CQ, Ho SY, Zhang WS, Mai ZM, Xu L, et al. Smoking and nasopharyngeal carcinoma mortality: a cohort study of 101,823 adults in Guangzhou, China. BMC Cancer. 2015; 15:906. https://doi.org/10.1186/s12885-015-1902-9 PMID: 26573573